VSVladislav K. Sevostyanov

Vladislav K. Sevostyanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vladislav K. Sevostyanov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phelan-McDermid Syndrome in a 4-Year-Old Girl: A Case Report

    by Svetlana Erdes, Natalia Martynovich, Anastasia Kolchina, Natella Chincharauli, Nina Makretskaya, Liya Toropchina, Anatoly Khavkin, Vladislav Sevostyanov, Albina Polishchuk, Rita Bitieva, et al.

    Phelan-McDermid syndrome (PMS; OMIM #606232) is a rare genetic disorder caused by terminal or interstitial deletions involving chromosome 22q13 or by pathogenic variants in the SHANK3 gene, which plays a critical role in synaptic function and neurodevelopment. PMS is characterized by marked clinical heterogeneity, with core manifestations including neonatal hypotonia, intellectual disability, severe speech impairment, epilepsy, and autism spectrum disorder. We report the case of a 4-year-old girl presenting with intellectual disability, severe speech delay, and craniofacial dysmorphism. Cytogenetic and molecular cytogenetic analyses identified a ring chromosome 22, with variation in SHANK3 signal loss across tissues and retention of the 22q subtelomeric probe. This case highlights the importance of early genetic diagnosis for the timely identification of associated comorbidities and the initiation of multidisciplinary rehabilitation and developmental interventions, ultimately improving long-term functional outcomes and quality of life.

  • Vitamin D status in children with arthralgia in a metropolitan setting: a retrospective observational study

    by Vladislav K. Sevostyanov, Daria E. Fomina, Stanislav L. Balashov, Albina R. Polishchuk, Ekaterina V. Eronina, Denis I. Manukhin, Daria D. Chugunova, Albina S. Pestova, Marina A. Manina, Denis D. Rassokha, et al.

    Vitamin D deficiency in children is associated with muscle weakness, arthralgia, and nonspecific growing pains. Low serum 25(OH)D concentration is associated with an increased risk of autoimmune rheumatic diseases, including juvenile idiopathic arthritis. The high prevalence of vitamin D deficiency and insufficiency in the Russian pediatric population underscores the need for its assessment to identify risk factors for joint pathology. Objective. To assess the prevalence and structure of vitamin D deficiency (severe deficiency, deficiency, insufficiency) in children with arthralgia across different age groups based on a retrospective analysis. Patients and methods. A retrospective observational cross-sectional study was conducted based on the analysis of medical records of 264 patients aged 1–17 years who consulted a rheumatologist with complaints of joint pain. Serum 25(OH)D concentration was measured by high-performance liquid chromatography with tandem mass spectrometric detection. Statistical analysis included the Kruskal–Wallis test and Fisher's exact test. Results. Normal 25(OH)D concentration (≥30 ng/mL) was found in only 28.4% of patients, severe deficiency (<10 ng/mL) – in 9.1%, deficiency (10–19.9 ng/mL) – in 33.3%, insufficiency (20–29.9 ng/mL) – in 29.2%. No statistically significant differences by sex were found (p = 0.886). The proportion of children with normal vitamin D concentration decreased with age: in the 1–6 years group it was 45.2% (14/31), in the 7–11 years group – 33.3% (30/90), and in the 12–17 years group – 22.4% (32/143). When comparing proportions using Fisher's exact test, differences between the 1–6 years and 12–17 years groups, as well as between the 7–11 years and 12–17 years groups, were statistically significant (p = 0.013 and p = 0.030, respectively). The overall difference across the three age groups was also confirmed (p = 0.014). Conclusion. A reduced serum 25(OH)D concentration was found in the majority of children with arthralgia. The lowest vitamin D status was observed in the 12–17 years age group. The results justify the need to strengthen the prevention of vitamin D deficiency, especially in children older than 7 years. Key words: vitamin D, vitamin D deficiency, children, growing pains, arthralgia

  • Comprehensive assessment of adolescent health in Moscow

    by S.L. Balashov, V.K. Sevostyanov, A.A. Krepysheva, A.V. Makarova, O.A. Pozdnyakova, A.V. Trigubets, D.E. Fomina, D.D. Rassokha, Moscow Children’s City Polyclinic No 120, N.V. Babich, et al.

    Objective. To assess the health status of adolescents aged 15–17 years living in Moscow based on the results of comprehensive preventive examinations. Patients and methods. This retrospective analysis included findings of preventive medical examinations of 1,255 adolescents aged 15–17 living in Moscow between January 1, 2024, and December 31, 2024. Results. In most adolescents, indicators of height, body mass index and blood pressure were within the reference range. Among all patients, only 14.1% of adolescents were considered completely healthy, while 85.9% of adolescents had at least one disease or functional disorder. The leading pathologies were diseases of the eye and its adnexa, diseases of the musculoskeletal system and connective tissue, endocrine diseases, and eating disorders, which requires the development of clinical and organizational measures to prevent these diseases in adolescents. According to the results of a comprehensive assessment, 76.6% of patients were classified as health groups I and II, and 69.6% of adolescents were classified as the general physical training group. Conclusion. The results of this study indicate the need to develop and improve the organization of medical care for adolescents. The issue of establishing closer cooperation between educational and medical institutions is becoming increasingly relevant, as is the need to change the model of medical organizations, which will be focused on solving a range of tasks that go beyond the existing pediatric model. In most adolescents, indicators of height, body mass index and blood pressure were within the reference range. Key words: health groups, comprehensive health assessment, adolescents, preventive medical examinations, physical development, physical training groups

  • Safety of vaccination in children with juvenile idiopathic arthritis

    by D.D. Rassokha, Moscow Children'S City Polyclinic No 120, V.K. Sevostyanov, S.I. Erdes, O.A. Pozdnyakova, D.A. Iureva, N.V. Babich, P.S. Lototskay, Moscow Children'S City Polyclinic No 143, S.L. Balashov, et al.

    Objective. To assess the safety of vaccination in children (0-17 years inclusive) with juvenile idiopathic arthritis (JIA) in Moscow. Patients and methods. An observational analytical cross-sectional study including 400 patients with JIA was conducted. The minimum required sample size of the observational group was 328 patients. Results. Only 23.8% of patients (n = 95) continued to be vaccinated after the onset of JIA. The exacerbation of juvenile arthritis in patients after achieving remission was independent of continuation or discontinuation of vaccination (p = 0.139). Children with a complete vaccination schedule were less likely to have exacerbations than patients with an incomplete vaccination schedule (p = 0.044). Conclusion. Vaccination in children with JIA has been shown to be safe and does not lead to an increase in the number of exacerbations in the post-vaccination period. Further search for other factors that may influence the exacerbation of juvenile arthritis is required.

  • Vaccination and immunization coverage of children with juvenile idiopathic arthritis in Moscow: where are we now?

    by D.D. Rassokha, Moscow Children'S City Polyclinic No 120, V.K. Sevostyanov, D.V. Usenko, S.I. Erdes, N.V. Babich, P.S. Lototskaya, S.L. Balashov, A.R. Polishchuk, E.S. Zholobova, et al.

    Objective. To estimate the immunization coverage and vaccination rate of children (0-17 years of age inclusive) with juvenile idiopathic arthritis (JIA) for each individual infection according to the regional vaccination calendar in Moscow. Patients and Methods. An observational analytic cohort study including 753 patients with JIA and 753 healthy control children living in Moscow was conducted. Results. Patients with juvenile arthritis have lower immunization coverage than children without autoimmune disease; they are also less immunized compared with controls, but even the immunization rates of healthy children do not meet vaccination targets. Conclusion. The data from this study should be taken into account in order to optimize vaccine prophylaxis not only for patients with JIA but also for healthy children, as both groups require adjustment of the immunization schedule, approaches to immunoprophylaxis positioning and optimization of vaccination methods. Key words: vaccination, vaccine prophylaxis, immunization, epidemiology, juvenile arthritis

  • MORBIDITY STRUCTURE IN 14-YEARS-OLD RESIDENTS OF THE MOSCOW CITY (RUSSIA): CHECKUPS’ STUDY

    by A.R. Polishchuk, A.S. Romanova, M.Sh. Khaider, S.L. Balashov, V.K. Sevostyanov

    Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.


  • ANALYSIS OF THE SURVIVAL OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

    by V.K. Sevostyanov, P.S. Lototskaya, N.V. Babich, D.D. Rassoha, A.S. Novikov, S.L. Balashov, E.S. Zholobova, Moscow Moscow City Center For Pediatric Rheumatology With The Morozov Children’s City Clinical Hospital

    The problem of the survival of various genetically engineered biological drugs (GEBD) is of a current scientific interest. A clear analysis of the reasons for the withdrawal coupled with the GEBD switching algorithmizing would allow developing of the individual treatment plans and monitoring of the patients. The objective of the study was to analyze the survival of genetically engineered biological therapy in children with juvenile idiopathic arthritis (JIA) through identifying the frequency and structure of cases of switching/cancellation of GEBD. Materials and methods: based on the data obtained from the Moscow registry of children with rheumatic diseases, an observational analytical cross-sectional study was conducted, including patients with JIA aged 0 to 17 years old living in Moscow, who had a history of episodes of switching or cancellation of GEBD. The study was conducted from January, 2015 to December, 2021. Results: 1220 patients (35.8% male/64.2% female) with JIA were included in the study. The median age of patients was 11.0 (8.0; 15.0) years. The total number of prescribing of GEBD of the first and subsequent lines was 589 episodes in 531 patients, of which 46 patients had 64 episodes of switching or cancellation of GEBD, which accounted for 10.9% of all cases of prescribing of GEBD. In the structure of the reasons for the therapy change the secondary failure accounted for 57.8%, the primary failure - 12.5%, intolerance - 10.9%, de novo uveitis - 9.4%. Cancellation of the drug therapy due to the achievement of remission was noted in 6.2% of cases. There are statistically significant differences in the duration of therapy depending on the reason for discontinuation or replacement of therapy (p<0.001). More often, patients were transferred to adalimumab (29.3%), and when adalimumab was canceled, to tocilizumab and golimumab. In the event of tocilizumab discontinuation, the majority of patients were switched to canakinumab drug therapy. Conclusion: the presented analysis is one of a few studies of such kind that were ever conducted in Russia; it requires further accumulation and analysis of data, including cases of discontinuation of the drug therapy, switching between the drugs, as well as the duration of therapy before the event that caused the change or discontinuation of the drug therapy happened.


  • Pediatric rheumatology care in the Central Federal District of the Russian Federation

    by V.K. Sevostyanov, E.S. Zholobova, O.V. Baranova, K.S. Poemshina, A.I. Polukhina, A.S. Novikov, S.L. Balashov